- Home
- LU vs MLYS Comparison
LU vs MLYS Comparison
Compare LU & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LU
- MLYS
- Stock Information
- Founded
- LU 2005
- MLYS 2019
- Country
- LU China
- MLYS United States
- Employees
- LU N/A
- MLYS N/A
- Industry
- LU Finance: Consumer Services
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- LU Finance
- MLYS Health Care
- Exchange
- LU Nasdaq
- MLYS Nasdaq
- Market Cap
- LU 3.1B
- MLYS 3.1B
- IPO Year
- LU 2020
- MLYS 2023
- Fundamental
- Price
- LU $3.19
- MLYS $43.63
- Analyst Decision
- LU Hold
- MLYS Strong Buy
- Analyst Count
- LU 1
- MLYS 6
- Target Price
- LU $3.20
- MLYS $42.60
- AVG Volume (30 Days)
- LU 3.7M
- MLYS 1.4M
- Earning Date
- LU 10-21-2025
- MLYS 11-10-2025
- Dividend Yield
- LU N/A
- MLYS N/A
- EPS Growth
- LU N/A
- MLYS N/A
- EPS
- LU N/A
- MLYS N/A
- Revenue
- LU $4,671,260,668.00
- MLYS N/A
- Revenue This Year
- LU N/A
- MLYS N/A
- Revenue Next Year
- LU N/A
- MLYS N/A
- P/E Ratio
- LU N/A
- MLYS N/A
- Revenue Growth
- LU N/A
- MLYS N/A
- 52 Week Low
- LU $2.22
- MLYS $8.24
- 52 Week High
- LU $4.57
- MLYS $44.80
- Technical
- Relative Strength Index (RSI)
- LU 40.05
- MLYS 71.05
- Support Level
- LU $3.51
- MLYS $37.54
- Resistance Level
- LU $3.75
- MLYS $44.80
- Average True Range (ATR)
- LU 0.26
- MLYS 2.36
- MACD
- LU -0.11
- MLYS -0.34
- Stochastic Oscillator
- LU 3.17
- MLYS 83.55
About LU Lufax Holding Ltd each representing two (2)
Lufax Holding Ltd is a technology-empowered personal financial services platform in China. The company address the large unmet demand for personal lending among small business owners as well as salaried workers in China and provides tailor-made wealth management solutions to China's middle class and affluent population. Its platform has two hubs namely Retail Credit Facilitation Hub and Wealth Management Hub.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.